Evidence map›Paper›PMID 31987001›Full record

ArticleEmerging microbes & infections2020

Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan.

Jasper Fuk-Woo Chan, Kin-Hang Kok, Zheng Zhu, Hin Chu, Kelvin Kai-Wang To, Shuofeng Yuan, Kwok-Yung Yuen

Erratum issued 5 registry-linked trialsOpen access · goldAbstract read
In one paragraph

Article in Emerging microbes & infections, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 5 registered trials, which are not on this map. Cited by 1,529 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1,529citing papers in PubMed, 3 pooled it
77.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04328493 phase2completednot on this map

A Multi Center Randomized Open Label Trial on the Safety and Efficacy of Chloroquine for the Treatment of Hospitalized Adults With Laboratory Confirmed SARS-CoV-2 Infection in Vietnam

TypeinterventionalSponsorOxford University Clinical Research Unit, VietnamRan2020 to 2020Enrolled10ConditionsSARS-CoV-2 Infection, COVID-19ArmsChloroquine phosphate
NCT04365725 completednot on this map

Multicenter, Retrospective Study of the Effects of Remdesivir in the Treatment of Severe Covid-19 Infections.

TypeobservationalSponsorAssistance Publique - Hôpitaux de ParisRan2020 to 2020Enrolled84ConditionsCOVID-19ArmsRemdesivir
NCT05137509 unknown statusnot on this mapstarted 2022, after this paper: background citation

YKL -40 as Anew Biomarker in COVID -19 Patients

TypeobservationalSponsorAssiut UniversityRan2022 to 2024Enrolled100ConditionsCOVID-19ArmsComputerized Tomography
NCT05205746 phase2completednot on this mapstarted 2021, after this paper: background citation

Phase II Study to Evaluate Immunogenicity and Safety in Subjects With Evidence of Prior Immunity to SARS-CoV-2 of a Single Intramuscular or Intranasal Dose of the Live Recombinant Newcastle Disease Virus Based AVX/COVID-12 Vaccine

TypeinterventionalSponsorLaboratorio Avi-Mex, S.A. de C.V.Ran2021 to 2023Enrolled158ConditionsSARS CoV 2 InfectionArmsRecombinant NDV Vectored Vaccine for SARS-CoV-2, Placebo
NCT05710783 phase2 / phase3completednot on this mapstarted 2022, after this paper: background citation

Phase II/III Parallel, Double-blind, Non-inferiority Study With Active Control, to Evaluate the Immunogenicity and Safety of a Booster Immunization Scheme With a Single Intramuscular Dose of the Recombinant Vaccine Against SARS-CoV-2

TypeinterventionalSponsorLaboratorio Avi-Mex, S.A. de C.V.Ran2022 to 2023Enrolled4,065ConditionsSARS-CoV-2 InfectionArmsAVX-COVID/12, ChAdOx-1-S[recombinant]
3 · Its place in the literature

Who cites it

1,529 citing papers in PubMed, 3 syntheses or guidelines pooled it, 3,260 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

1,469 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Jasper Fuk-Woo ChanState Key Laboratory of Emerging Infectious Diseases, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China.ORCID 0000-0001-6336-6657
Kin-Hang KokState Key Laboratory of Emerging Infectious Diseases, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China.ORCID 0000-0003-3426-332X
Zheng ZhuDepartment of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China.
Hin ChuState Key Laboratory of Emerging Infectious Diseases, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China.
Kelvin Kai-Wang ToState Key Laboratory of Emerging Infectious Diseases, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China.
Shuofeng YuanState Key Laboratory of Emerging Infectious Diseases, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China.
Kwok-Yung YuenDepartment of Clinical Microbiology and Infection Control, The University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong, People's Republic of China.
University of Hong Kong · HKUniversity of Hong Kong - Shenzhen Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A mysterious outbreak of atypical pneumonia in late 2019 was traced to a seafood wholesale market in Wuhan of China. Within a few weeks, a novel coronavirus tentatively named as 2019 novel coronavirus (2019-nCoV) was announced by the World Health Organization. We performed bioinformatics analysis on a virus genome from a patient with 2019-nCoV infection and compared it with other related coronavirus genomes. Overall, the genome of 2019-nCoV has 89% nucleotide identity with bat SARS-like-CoVZXC21 and 82% with that of human SARS-CoV. The phylogenetic trees of their orf1a/b, Spike, Envelope, Membrane and Nucleoprotein also clustered closely with those of the bat, civet and human SARS coronaviruses. However, the external subdomain of Spike's receptor binding domain of 2019-nCoV shares only 40% amino acid identity with other SARS-related coronaviruses. Remarkably, its orf3b encodes a completely novel short protein. Furthermore, its new orf8 likely encodes a secreted protein with an alpha-helix, following with a beta-sheet(s) containing six strands. Learning from the roles of civet in SARS and camel in MERS, hunting for the animal source of 2019-nCoV and its more ancestral virus would be important for understanding the origin and evolution of this novel lineage B

Indexed as

Genome, ViralAmino Acid SequenceBetacoronavirusChinaCoronavirus InfectionsCOVID-19HumansPhylogenyPneumonia, ViralSARS-CoV-2Sequence Analysis, ProteinTravelViral ProteinsViral ProteinsbioinformaticsCoronavirusemerginggenomerespiratorySARSvirusWuhan

Identifiers

PMID31987001
PMCPMC7067204
OpenAlexW3003464757

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.